some default text...
Previous Section Index Home Page


Medicines Commission

Mr. Simon Hughes: To ask the Secretary of State for Health if he will list the chairmen of the Medicines Commission since the inception of the Medicines Commission and give for each chairman the dates on which the chairmanship started and finished, together with the total duration of the chairmanship and if the individual concerned had served as a member of the Medicines Commission other than as chairman. [12921]

Mr. Malone: The available information is as follows:

Start and finish date
Sir Derrick Dunlop MD FRCP FRCPed(Chairman) 1969 to December 1971
Lord Rosenheim KBE MD FRCP(Member) 1969 to December 1971 (Chairman) January 1972 to December 1972 (1 year)
Professor A. Wilson CBE PhD MD FRCP FPS(Member) 1969 to October 1974 (Acting Chairman) December 1972 to mid 1973
Sir Ronald Bodley Scott GCVO MA MD(Chairman) Mid 1973 to December 1975
Professor W. Butterfield OBE MA MD DM FRCP FACP(Member) January 1975 to December 1975 (1 year) (Chairman) January 1976 to December 1981 (6 years)
Professor Dame Rosalind Hurley DBE LLB MD DUniv(Surrey) FRCPath FFPM(Hon) FRCOG(Chairman) 1982 to December 1993 (12 years)
Professor D. Lawson CBE MD FRCPEdin FRCPGlasg FFPM(Chairman) January 1994 to Present (2 years 1 month)

Mr. Hughes: To ask the Secretary of State for Health if he will list the occasions when the Medicines Commission has exercised its powers under section 3 of the Medicines Act 1968, and for each occasion give the date and nature of the issues examined, at whose request the powers were exercised, and if the results of the deliberations of the commission were published. [12923]

Mr. Malone: Section 3 of the Medicines Act 1968 sets out all of the general functions assigned to the Medicines Commission by or under the Act. To provide the information in respect of all the matters considered by the commission since it was established in 1969 would incur

8 Feb 1996 : Column: 346

disproportionate cost. Details of matters considered by the commission are published in annual reports which are laid before the House and copies of which are available in the Library.

Mr. Hughes: To ask the Secretary of State for Health if he will list the occasions since 1968 when the Medicines Commission reviewed the committees established under section 4 of the Medicines Act 1968. [12975]

Mr. Malone: Under section 5 of the Medicines Act 1968, all section 4 committees are required to report to the Medicines Commission annually with respect to the performance of their functions. Copies of the reports are placed in the Libraries of both Houses.

Clinical Trials

Mr. Simon Hughes: To ask the Secretary of State for Health (1) what clinical trials conducted under a clinical trials exemption certificate were terminated between 1 October 1995 and 30 November 1995 at the request of the licensing authority on grounds of safety; [12922]

Mr. Malone: Any company, or investigator, wishing to conduct a clinical trial with third generation progestogens or their metabolites, would have to apply to the Medicines Control Agency in accordance with the Medicines Act 1968 and its secondary legislation, and would have to provide a justification for the use of third generation progestogens taking into account the recent advice of the Committee on Safety of Medicines in its letter dated 18 October 1995. Any regulatory action relating to clinical trials is treated in confidence between the licensing authority and the company or investigator concerned.

Medicines Act

Mr. Simon Hughes: To ask the Secretary of State for Health if he will list the sub-committees established under powers conferred by section 1 (c) of schedule 1 to the Medicines Act 1968 or section 6 of the Medicines Commission and Committees Regulations 1970, giving for each sub-committee the date on which ministerial approval was given for the establishing of the sub-committee, which Minister or Ministers gave such approval, the date on which the sub-committee first met and, where applicable, the date of the final meeting of the sub-committee. [12924]

Mr. Malone: The available information for sub-committees established by powers conferred by section 1(c) of schedule 1 to the Medicines Act 1968 is contained in the annual reports of the section 4 committees of the Medicines Act 1968, copies of which are available in the Library.

Medicines Control Agency

Mr. Simon Hughes: To ask the Secretary of State for Health on what date arrangements were made by the Medicines Control Agency for the meetings with Professor Walter Spitzer and colleagues which were held

8 Feb 1996 : Column: 347

on Monday 9 October 1995 and Tuesday 10 October 1995. [12925]

Mr. Malone: The arrangements were made in late September 1995.

Committee on Safety of Medicines

Mr. Simon Hughes: To ask the Secretary of State for Health what written reports from the transnational study were received by the licensing authority before to the meeting of the Committee on Safety of Medicines held on 13 October 1995. [12968]

Mr. Malone: I refer the hon. Member to the reply I gave the hon. Member for Gordon (Mr. Bruce) on 19 December 1995, Official Report, column 1149.

Mr. Hughes: To ask the Secretary of State for Health if he will list the scheduled and actual meeting dates between 1 January 1995 and 31 December 1995 of the Committee on Safety of Medicines and its pharmacovigilance sub-committee. [12969]

Mr. Malone: The scheduled and actual meeting dates of the Committee on Safety of Medicines were as follows:


The scheduled meeting dates of the pharmacovigilance sub-committee were as follows:



    3 January 1995
    31 January 1995
    28 February 1995
    28 March 1995
    2 May 1995
    6 June 1995
    4 July 1995
    5 September 1995
    3 October 1995
    31 October 1995
    28 November 1995

The meetings scheduled for 31 January 1995 and 28 March 1995 were cancelled.

Mr. Hughes: To ask the Secretary of State for Health (1) if he will list travel and subsistence expenses paid to the members of the Committee on Safety of Medicines for journeys in October 1995; and if, for each payment, he will identify the committee members concerned, the starting point, starting date, finishing point and finishing date for each journey, and list separately the sums of travel and subsistence expenses paid; [12920]

8 Feb 1996 : Column: 348

Mr. Malone: No. This information cannot be provided for reasons of confidentiality.

EU Legislation

Mr. Steen: To ask the Secretary of State for Health on which occasions in the last three years officials have vetoed draft EC legislation on the grounds that a fiche d'impact had not been correctly prepared. [13643]

Mr. Horam: The correct preparation of fiches d'impact is a very important part of our consideration of proposals for EC legislation. It is one of the factors taken into account when Ministers consider the United Kingdom's negotiating position on a particular proposal.

Renal Services

Mr. Churchill: To ask the Secretary of State for Health what estimate he has made of the number of patients who die each year due to renal failure through the non-availability of dialysis machines to treat them; and if he will make a statement on the remedial measures he is taking. [14061]

Mr. Horam: This information is not available. It is for individual health authorities to allocate resources to renal services based on an assessment of the needs of their population and taking account of local priorities. Good practice guidance has been issued to help authorities to carry out a proper assessment of need for patients with renal failure. Purchasing guidance will be issued to health authorities shortly.

Mr. Churchill: To ask the Secretary of State for Health on what date he received the national review of renal services; and if he will now publish it. [14062]

Mr. Horam: My right hon. Friend the then Secretary of State received the report of the national review of renal services in December 1994. We are currently considering a number of issues as to how to take this forward. This includes related guidance on purchasing renal services to be issued to health authorities in time for the next contracting round.


Next Section Index Home Page